Cargando…

Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder

INTRODUCTION: States’ approaches to addressing prenatal substance use are widely heterogeneous, ranging from supportive policies that enhance access to substance use disorder (SUD) treatment to punitive policies that criminalize prenatal substance use. We studied the effect of these prenatal substan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabatabaeepour, Nadia, Morgan, Jake R., Jalali, Ali, Kapadia, Shashi N., Meinhofer, Angélica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357143/
https://www.ncbi.nlm.nih.gov/pubmed/35577664
http://dx.doi.org/10.1016/j.jsat.2022.108800
_version_ 1784763664870408192
author Tabatabaeepour, Nadia
Morgan, Jake R.
Jalali, Ali
Kapadia, Shashi N.
Meinhofer, Angélica
author_facet Tabatabaeepour, Nadia
Morgan, Jake R.
Jalali, Ali
Kapadia, Shashi N.
Meinhofer, Angélica
author_sort Tabatabaeepour, Nadia
collection PubMed
description INTRODUCTION: States’ approaches to addressing prenatal substance use are widely heterogeneous, ranging from supportive policies that enhance access to substance use disorder (SUD) treatment to punitive policies that criminalize prenatal substance use. We studied the effect of these prenatal substance use policies (PSUPs) on medications for opioid use disorder (OUD) treatment, including buprenorphine, naltrexone, and methadone, psychosocial services for SUD treatment, opioid prescriptions, and opioid overdoses among commercially insured pregnant females with OUD. We evaluated: (1) punitive PSUPs criminalizing prenatal substance use or defining it as child maltreatment; (2) supportive PSUPs granting pregnant females priority access to SUD treatment; and (3) supportive PSUPs funding targeted SUD treatment programs for pregnant females. METHODS: We analyzed 2006–2019 MarketScan Commercial Claims and Encounters data. The longitudinal sample comprised females aged 15–45 with an OUD diagnosis at least once during the study period. We estimated fixed effects models that compared changes in outcomes between pregnant and nonpregnant females, in states with and without a PSUP, before and after PSUP implementation. RESULTS: Our analytical sample comprised 2,438,875 person-quarters from 164,538 unique females, of which 13% were pregnant at least once during the study period. We found that following the implementation of PSUPs funding targeted SUD treatment programs, the proportion of opioid overdoses decreased 45% and of any OUD medication increased 11%, with buprenorphine driving this increase (13%). The implementation of SUD treatment priority PSUPs was not associated with significant changes in outcomes. Following punitive PSUP implementation, the proportion receiving psychosocial services for SUD (12%) and methadone (30%) services decreased. In specifications that estimated the impact of criminalizing policies only, the strongest type of punitive PSUP, opioid overdoses increased 45%. CONCLUSION: Our findings suggest that supportive approaches that enhance access to SUD treatment may effectively reduce adverse maternal outcomes associated with prenatal opioid use. In contrast, punitive approaches may have harmful effects. These findings support leading medical organizations’ stance on PSUPs, which advocate for supportive policies that are centered on increased access to SUD treatment and safeguard against discrimination and stigmatization. Our findings also oppose punitive policies, as they may intensify marginalization of pregnant females with OUD seeking treatment.
format Online
Article
Text
id pubmed-9357143
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-93571432022-09-01 Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder Tabatabaeepour, Nadia Morgan, Jake R. Jalali, Ali Kapadia, Shashi N. Meinhofer, Angélica J Subst Abuse Treat Article INTRODUCTION: States’ approaches to addressing prenatal substance use are widely heterogeneous, ranging from supportive policies that enhance access to substance use disorder (SUD) treatment to punitive policies that criminalize prenatal substance use. We studied the effect of these prenatal substance use policies (PSUPs) on medications for opioid use disorder (OUD) treatment, including buprenorphine, naltrexone, and methadone, psychosocial services for SUD treatment, opioid prescriptions, and opioid overdoses among commercially insured pregnant females with OUD. We evaluated: (1) punitive PSUPs criminalizing prenatal substance use or defining it as child maltreatment; (2) supportive PSUPs granting pregnant females priority access to SUD treatment; and (3) supportive PSUPs funding targeted SUD treatment programs for pregnant females. METHODS: We analyzed 2006–2019 MarketScan Commercial Claims and Encounters data. The longitudinal sample comprised females aged 15–45 with an OUD diagnosis at least once during the study period. We estimated fixed effects models that compared changes in outcomes between pregnant and nonpregnant females, in states with and without a PSUP, before and after PSUP implementation. RESULTS: Our analytical sample comprised 2,438,875 person-quarters from 164,538 unique females, of which 13% were pregnant at least once during the study period. We found that following the implementation of PSUPs funding targeted SUD treatment programs, the proportion of opioid overdoses decreased 45% and of any OUD medication increased 11%, with buprenorphine driving this increase (13%). The implementation of SUD treatment priority PSUPs was not associated with significant changes in outcomes. Following punitive PSUP implementation, the proportion receiving psychosocial services for SUD (12%) and methadone (30%) services decreased. In specifications that estimated the impact of criminalizing policies only, the strongest type of punitive PSUP, opioid overdoses increased 45%. CONCLUSION: Our findings suggest that supportive approaches that enhance access to SUD treatment may effectively reduce adverse maternal outcomes associated with prenatal opioid use. In contrast, punitive approaches may have harmful effects. These findings support leading medical organizations’ stance on PSUPs, which advocate for supportive policies that are centered on increased access to SUD treatment and safeguard against discrimination and stigmatization. Our findings also oppose punitive policies, as they may intensify marginalization of pregnant females with OUD seeking treatment. 2022-09 2022-05-10 /pmc/articles/PMC9357143/ /pubmed/35577664 http://dx.doi.org/10.1016/j.jsat.2022.108800 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Tabatabaeepour, Nadia
Morgan, Jake R.
Jalali, Ali
Kapadia, Shashi N.
Meinhofer, Angélica
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
title Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
title_full Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
title_fullStr Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
title_full_unstemmed Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
title_short Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
title_sort impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357143/
https://www.ncbi.nlm.nih.gov/pubmed/35577664
http://dx.doi.org/10.1016/j.jsat.2022.108800
work_keys_str_mv AT tabatabaeepournadia impactofprenatalsubstanceusepoliciesoncommerciallyinsuredpregnantfemaleswithopioidusedisorder
AT morganjaker impactofprenatalsubstanceusepoliciesoncommerciallyinsuredpregnantfemaleswithopioidusedisorder
AT jalaliali impactofprenatalsubstanceusepoliciesoncommerciallyinsuredpregnantfemaleswithopioidusedisorder
AT kapadiashashin impactofprenatalsubstanceusepoliciesoncommerciallyinsuredpregnantfemaleswithopioidusedisorder
AT meinhoferangelica impactofprenatalsubstanceusepoliciesoncommerciallyinsuredpregnantfemaleswithopioidusedisorder